Picture of Sono-Tek logo

SOTK — Sono-Tek News Story

0.000.00%
us flag iconLast trade - 00:00
IndustrialsAdventurousSmall CapHigh Flyer

Sono-Tek Q2 profit misses estimates as higher costs outweigh margin gains

Sono-Tek Q2 profit misses estimates as higher costs outweigh margin gains


Overview

  • US ultrasonic coating systems maker's Q2 revenue rose 1% yr/yr, gross margin expanded to 53%

  • EPS for Q2 declined to $0.02 from $0.03 in prior-year period

  • Company reiterates flat to modest revenue growth guidance for FY 27, citing timing of large orders


Outlook

  • Sono-Tek reiterates expectation of flat to modest revenue growth for FY 27

  • Company says recent large orders significantly increase revenue visibility for FY 28

  • Sono-Tek sees quarter-to-quarter revenue variability due to timing of large orders


Result Drivers

  • MEDICAL SALES SURGE - Co said medical market sales rose 209% in Q2, led by shipments of balloon coating and specialty stent-coating systems

  • PRODUCT AND GEOGRAPHIC MIX - Co attributed expanded Q2 gross margin to an unusually favorable product and geographic mix

  • HIGHER OPERATING EXPENSES - Co said increased operating expenses partially offset gross profit gains in Q2


Company press release: ID:nGNX5bqY4J


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Miss

$5.23 mln

$5.54 mln (2 Analysts)

Q2 EPS

Miss

$0.02

$0.04 (2 Analysts)

Q2 Net Income

$366,000


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the industrial machinery & equipment peer group is "buy"

  • Wall Street's median 12-month price target for Sono-Tek Corp is $8.50, about 19.4% above its October 13 closing price of $7.12

  • The stock recently traded at 58 times the next 12-month earnings vs. a P/E of 55 three months ago


Reuters Recommended Reads

  • Oct 12 - Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial

  • Oct 12 - Bristol Myers radiopharma cancer drug slows rare tumor progression in study


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Sono-Tek

See all news